The maker of life science research and clinical diagnostic products could trade sideways for awhile before a sustained advance begins.
The stock bottomed in June/July and have worked higher.
Will we see a move from aggressive selling to aggressive buying?
These recently downgraded names are displaying both quantitative and technical deterioration.
The shares gapped higher Friday to refresh the uptrend.
The diversified technology giant has been bearish for months and is likely to remain so after reducing its full-year revenue and profit forecasts.
These recently downgraded names are displaying both quantitative and technical deterioration.
Here's our trading strategy for the shares.
The technical signals of the genome editing company are largely bearish and indicate its stock is poised to weaken.
Here's what traders should do now.